Inventor · disambiguated record
Stanley L. Hazen
Also filed as: HAZEN STANLEY · HAZEN STANLEY L · HAZEN Stanley Leon
58 granted patents·29 pending applications·184 citations·filing 2002–2024
98Inventor score
Files withCLEVELAND CLINIC FOUND30CLEVELAND CLINIC FOUNDATION18HAZEN STANLEY L15PROCTER & GAMBLE9HAZEN STANLEY4
Top patents by PatentIndex Score
87 records- 0195US9694020B2Treating and preventing disease with TMA and TMAO lowering agentsCLEVELAND CLINIC FOUND·Filed 2015·Granted Jul 4, 2017·8 cites·8 claims
- 0294US10933072B2Treating and preventing disease with TMA and TMAO lowering agentsCLEVELAND CLINIC FOUND·Filed 2019·Granted Mar 2, 2021·4 cites·17 claims
- 0394US8143224B2Oxidant resistant apolipoprotein A-1 and mimetic peptidesSMITH JONATHAN D·Filed 2008·Granted Mar 27, 2012·17 cites·18 claims
- 0492US9168233B2Treatment and prevention of cardiovascular disease and thrombosisCLEVELAND CLINIC FOUNDATION·Filed 2013·Granted Oct 27, 2015·11 cites·12 claims
- 0592US7223552B2Myeloperoxidase, a risk indicator for cardiovascular diseaseCLEVELAND CLINIC FOUNDATION·Filed 2002·Granted May 29, 2007·33 cites·23 claims
- 0691US10117879B2Treating and preventing disease with TMA and TMAO lowering agentsCLEVELAND CLINIC FOUND·Filed 2017·Granted Nov 6, 2018·3 cites·13 claims
- 0789US11911399B2Treating and preventing disease with TMA and TMAO lowering agentsCLEVELAND CLINIC FOUND·Filed 2021·Granted Feb 27, 2024·1 cites·14 claims
- 0888US10613044B2NMR quantification of TMAOLIPOSCIENCE INC·Filed 2016·Granted Apr 7, 2020·2 cites·14 claims
- 0988US9541620B2NMR quantification of TMAOLIPOSCIENCE INC·Filed 2013·Granted Jan 10, 2017·5 cites·24 claims
- 1088US8536117B2Oxidant resistant apolipoprotein A-1 and mimetic peptidesSMITH JONATHAN D·Filed 2012·Granted Sep 17, 2013·10 cites·16 claims
- 1187US2024165131A1Treating and preventing disease with tma and tmao lowering agentsCLEVELAND CLINIC FOUND·Filed 2024·Application pending·0 cites
- 1286US2024125719A1NMR Quantification of TMAOLIPOSCIENCE INC·Filed 2023·Application pending·0 cites
- 1385US10551372B2Trimethylamine compounds as risk predictors of cardiovascular diseaseCLEVELAND CLINIC FOUND·Filed 2016·Granted Feb 4, 2020·2 cites·5 claims
- 1485US7771954B2Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agentsCLEVELAND CLINIC FOUNDATION·Filed 2006·Granted Aug 10, 2010·10 cites·15 claims
- 1584US9051393B2Oxidant resistant apolipoprotein A-1 and mimetic peptidesCLEVELAND CLINIC FOUNDATION·Filed 2013·Granted Jun 9, 2015·2 cites·24 claims
- 1684US8338110B2Risk markers for cardiovascular diseaseHAZEN STANLEY L·Filed 2010·Granted Dec 25, 2012·8 cites·14 claims
- 1784US7378396B2Therapeutic agents and methods for cardiovascular diseaseCLEVELAND CLINIC FOUNDATION·Filed 2005·Granted May 27, 2008·5 cites·11 claims
- 1883US7459286B1Assessing the risk of a major adverse cardiac event in patients with chest painCLEVELAND CLINIC FOUNDATION·Filed 2004·Granted Dec 2, 2008·16 cites·24 claims
- 1982US11771659B2Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathwayCLEVELAND CLINIC FOUND·Filed 2018·Granted Oct 3, 2023·1 cites·20 claims
- 2082US10983100B2Trimethylamine-containing compounds for diagnosis and prediction of diseaseCLEVELAND CLINIC FOUND·Filed 2019·Granted Apr 20, 2021·3 cites·4 claims
- 2182US7776563B2Methods for identifying agents for treating cardiovascular disease using inhibition of myeloperoxidase bindingCLEVELAND CLINIC FOUNDATION·Filed 2008·Granted Aug 17, 2010·3 cites·5 claims
- 2281US10064830B2Treatment and prevention of cardiovascular disease and thrombosisCLEVELAND CLINIC FOUND·Filed 2017·Granted Sep 4, 2018·1 cites·10 claims
- 2380US9140703B2Combined F2-isoprostane and myeloperoxidase detection, a risk indicator for cardiovascular diseaseHAZEN STANLEY L·Filed 2010·Granted Sep 22, 2015·2 cites·1 claims
- 2480US7780950B2Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agentsCLEVELAND CLINIC FOUNDATION·Filed 2003·Granted Aug 24, 2010·6 cites·34 claims
- 2579US11331280B2Methods for inhibiting conversion of choline to trimethylamine (TMA)PROCTER & GAMBLE·Filed 2019·Granted May 17, 2022·2 cites·5 claims
- 2679US10241093B2Trimethylamine-containing compounds for diagnosis and prediction of diseaseHAZEN STANLEY L·Filed 2011·Granted Mar 26, 2019·4 cites·4 claims
- 2776US8349581B2Assessing the risk of a major adverse cardiac event in patients with chest painCLEVELAND CLINIC FOUNDATION·Filed 2008·Granted Jan 8, 2013·3 cites·8 claims
- 2876US7781219B2Risk markers for cardiovascular diseaseCLEVELAND CLINIC FOUNDATION·Filed 2004·Granted Aug 24, 2010·8 cites·45 claims
- 2975US12092648B2Detection of glucuronidated and 3-bromotyrosineCLEVELAND CLINIC FOUND·Filed 2022·Granted Sep 17, 2024·0 cites·8 claims
- 3074US2024139120A1Treating disease and promoting weight loss by inhibiting the tma/fmo3/tmao pathwayCLEVELAND CLINIC FOUND·Filed 2023·Application pending·0 cites
- 3173US11782002B2NMR quantification of TMAOLIPOSCIENCE INC·Filed 2020·Granted Oct 10, 2023·0 cites·19 claims
- 3272US9423405B2Trimethylamine compounds as risk predictors of cardiovascular diseaseHAZEN STANLEY L·Filed 2008·Granted Aug 23, 2016·5 cites·20 claims
- 3371US9005904B2Risk markers for cardiovascular diseaseCLEVELAND CLINIC FOUNDATION·Filed 2014·Granted Apr 14, 2015·1 cites·13 claims
- 3471US2019038642A1Treating and preventing disease with tma and tmao lowering agentsCLEVELAND CLINIC FOUND·Filed 2018·Application pending·0 cites
- 3570US10780072B2Methods for inhibiting conversion of choline to trimethylamine (TMA)PROCTER & GAMBLE·Filed 2016·Granted Sep 22, 2020·1 cites·3 claims
- 3670US8722344B2Risk markers for cardiovascular diseaseHAZEN STANLEY L·Filed 2012·Granted May 13, 2014·1 cites·9 claims
- 3770US8628935B2PON1 as a marker for heart failureHAZEN STANLEY L·Filed 2010·Granted Jan 14, 2014·1 cites·11 claims
- 3870US2021270855A1Pip2 as a marker for hdl function and cardiovascular disease riskCLEVELAND CLINIC FOUND·Filed 2021·Application pending·0 cites
- 3969US12055535B2Trimethylamine compounds as risk predictors of cardiovascular diseaseCLEVELAND CLINIC FOUND·Filed 2020·Granted Aug 6, 2024·0 cites·10 claims
- 4069US11249091B2Detection of glucuronidated and 3-bromotyrosineCLEVELAND CLINIC FOUND·Filed 2019·Granted Feb 15, 2022·0 cites·17 claims
- 4168US9581597B2Myeloperoxidase, a risk indicator for cardiovascular diseaseCLEVELAND CLINIC FOUND·Filed 2016·Granted Feb 28, 2017·0 cites·2 claims
- 4268US9265736B2Treatment of cardiovascular disease and thrombosisHAZEN STANLEY·Filed 2012·Granted Feb 23, 2016·1 cites·16 claims
- 4368US7648840B2Diagnosis of conditions associated with decreased arginine bioavailabilityCHILDRENS HOSP & RES CT OAK·Filed 2005·Granted Jan 19, 2010·2 cites·19 claims
- 4467US9575065B2Myeloperoxidase, a risk indicator for cardiovascular diseaseCLEVELAND CLINIC FOUND·Filed 2016·Granted Feb 21, 2017·0 cites·1 claims
- 4567US9435808B2Myeloperoxidase, a risk indicator for cardiovascular diseaseCLEVELAND CLINIC FOUND·Filed 2015·Granted Sep 6, 2016·0 cites·4 claims
- 4666US9164095B2Myeloperoxidase, a risk indicator for cardiovascular diseaseHAZEN STANLEY·Filed 2005·Granted Oct 20, 2015·0 cites·9 claims
- 4765US9612242B2Combined F2-isoprostane and myleoperoxidase detection, a risk indicator for cardiovascular diseaseCLEVELAND CLINIC FOUND·Filed 2015·Granted Apr 4, 2017·0 cites·3 claims
- 4865US2025334558A1Total hydrogen sulfide quantificationCLEVELAND CLINIC FOUND·Filed 2023·Application pending·0 cites
- 4964US8309320B2Diagnosis of conditions associated with decreased arginine bioavailabilityMORRIS CLAUDIA R·Filed 2009·Granted Nov 13, 2012·1 cites·17 claims
- 5063US2020209264A1Pip2 as a marker for hdl function and cardiovascular disease riskCLEVELAND CLINIC FOUND·Filed 2019·Application pending·0 cites
Showing the top 50 of 87 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →